Premium
Does carbamazepine cause disturbances in calcium metabolism in epileptic patients?
Author(s) -
Tjellesen Lone,
Nilas Lisbeth,
Christiansen Claus
Publication year - 1983
Publication title -
acta neurologica scandinavica
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.967
H-Index - 95
eISSN - 1600-0404
pISSN - 0001-6314
DOI - 10.1111/j.1600-0404.1983.tb04809.x
Subject(s) - carbamazepine , osteomalacia , phenytoin , anticonvulsant , primidone , endocrinology , medicine , calcium , epilepsy , pharmacology , bone remodeling , alkaline phosphatase , chemistry , vitamin d and neurology , enzyme , biochemistry , psychiatry
ABSTRACT Calcium metabolism was examined in 30 adult epileptic outpatients on carbamazepine monotherapy. The patients had a normal bone mass, evaluated both on the forearm (100 ± 13 of normal) and on the total skeleton (102 ± 15), and normal serum concentrations of 250HD. The serum calcium was decreased ( P < 0.001) and the serum alkaline phosphatase increased ( P < 0.001). The clinical significance of our study is that monotherapy with carbamazepine does not have the side effects on bone metabolism known as “anticonvulsant osteomalacia”. Our results further question the connection between liver enzyme induction and anticonvulsant osteomalacia, since carbamazepine possesses the same potency of liver enzyme induction as phenytoin. Further studies on epileptic outpatients will be necessary in order to elucidate the connection between treatment with anticonvulsant drugs and anticonvulsant osteomalacia.